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(CARRA) systemic Juvenile Idiopathic
Arthritis Consensus Treatment Plans
Yukiko Kimura1* , Sriharsha Grevich2, Timothy Beukelman3, Esi Morgan4, Peter A. Nigrovic5, Kelly Mieszkalski6,
T Brent Graham7, Maria Ibarra8, Norman Ilowite9, Marisa Klein-Gitelman10, Karen Onel11, Sampath Prahalad12,
Marilynn Punaro13, Sarah Ringold2, Dana Toib14, Heather Van Mater15, Jennifer E. Weiss1, Pamela F. Weiss16,
Laura E. Schanberg15 and for the CARRA Registry Investigators

Abstract
Objectives: To assess the feasibility of studying the comparative effectiveness of the Childhood Arthritis and
Rheumatology Research Alliance (CARRA) consensus treatment plans (CTPs) for systemic Juvenile Idiopathic Arthritis
(JIA) using an observational registry.
Methods: Untreated systemic JIA patients enrolled in the CARRA Registry were begun on one of 4 CTPs chosen by the
treating physician and patient/family (glucocorticoid [GC] alone; methotrexate [MTX] ± GC; IL1 inhibitor [IL1i] ± GC; IL6
inhibitor [IL6i] ± GC). The primary outcome of clinical inactive disease (CID) without current GC use was assessed at
9 months. Trial registration: clinicaltrials.gov NCT01697254; first registered 9/28/12 (retrospectively enrolled).
Results: Thirty patients were enrolled at 13 sites; eight patients were started on a non-biologic CTP (2 GC, 6 MTX) and
22 patients on a biologic CTP (12 IL1i, 10 IL6i) at disease onset. Demographic and disease features were similar between
CTP groups. CTP choice appeared to segregate by site preference. CID off GC was achieved by 37% (11 of 30) including
11/22 (50%) starting a biologic CTP compared to 0/8 starting a non-biologic CTP (p = 0.014). There were four serious
adverse events: two infections, one appendicitis and one macrophage activation syndrome.
Conclusions: The CARRA systemic JIA CTP pilot study demonstrated successful implementation of CTPs using the
CARRA registry infrastructure. Having demonstrated feasibility, a larger study using CTP response to better determine
the relative effectiveness of treatments for new-onset systemic JIA is now underway.
Keywords: Systemic Juvenile Idiopathic Arthritis, Still’s disease, Biologic response modifiers, Comparative effectiveness,
Pediatric rheumatology, Registries

Background
Systemic Juvenile Idiopathic Arthritis (JIA) is a rare
childhood inflammatory disease associated with significant morbidity, and characterized by arthritis accompanied by high spiking fevers, plus additional features
such as rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis [1]. There is considerable
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variation in systemic JIA treatment, due in part to a
heterogeneous and somewhat unpredictable disease
course, differences in physician practices, and until
very recently, a lack of clinical trial data [2–5] and evidence based guidelines [6, 7]. Recent trials of IL-1 and
IL-6 inhibitors (IL1i and IL6i) which demonstrated
striking efficacy in systemic JIA were conducted in
children with established chronic disease, so little evidence exists for use of biologic agents in new-onset or
untreated systemic JIA. Nevertheless, many pediatric
rheumatologists currently treat with IL1i and/or IL6i
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early in the course of disease [8–10]. Intriguing data
from several uncontrolled case series suggest that early
use of these biologic agents might favorably alter the
potentially devastating outcomes of chronic persistent
systemic JIA [10, 11]. On the other hand, as many as
10–40% of patients may have a monocyclic course
which remits spontaneously within the first year [12, 13],
complicating the evaluation of treatment effectiveness in
early disease. An additional consideration is the question
of whether rare, potentially fatal cardiopulmonary complications may be associated with the increased use of these
agents specifically in systemic JIA [14].
With new options for treatment now commercially
available and FDA approved, there is an urgent need to
determine the relative effectiveness, safety and tolerability of commonly used treatments in systemic JIA.
While a blinded randomized multi-arm controlled clinical trial would be ideal, it would be cost-prohibitive,
require a very large sample size and likely not be feasible to perform in such a rare disease of childhood.
Comparative effectiveness research (CER) studies in an
observational, routine care setting are therefore a more
practical approach to examine which treatments are
effective and most appropriate for an individual child
[15, 16]. In such a study, physician choice (together
with patient/caregiver preferences) would be the primary determining factor for treatment selection. Such a
study could be successful if there were equipoise between most common treatments and if the treatments
and data collection were standardized and captured at
predetermined intervals. The development of Consensusderived standardized Treatment Plans (CTPs) for systemic
JIA funded by a National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Challenge Grant
(1RC1AR058605-01) to the Childhood Arthritis and
Rheumatology Research Alliance (CARRA) was a key step
in this process and in improving outcomes for patients
with systemic JIA [17, 18]. The methods by which the
CARRA CTPs were developed using CARRA-wide surveys to identify the current most commonly used treatments for systemic JIA and the standardization process
using consensus methodology are outlined in a previously
published article [17].
A pilot study comparing the published CARRA systemic JIA CTPs was funded by an Arthritis Foundation Innovative Research Grant and conducted in a
limited number of sites in order to test the acceptance and usability of these CTPs in preparation for a
future large comparative effectiveness study that
would utilize the broader CARRA Registry network.
This pilot study was conducted to assess the feasibility of conducting a larger more definitive CER study
and to identify possible issues that could arise in such
a study [19].
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Methods
Patients were enrolled in the CARRA Registry and
treated with one of the systemic JIA CTPs at 13 CARRA
Registry sites for 9 months during the period from 2011
to 2014. Funding from NIAMS via the American Recovery and Reinvestment Act (ARRA) in 2010 enabled the
CARRA Registry, a multi-center prospective observational study of children with pediatric rheumatic diseases
including JIA. Altogether, investigators enrolled over
9,500 patients in what is now called the CARRA Legacy
Registry, including more than 7,000 with JIA (>500 with
systemic JIA) at 60 sites over 3 years [9]. The CARRA
Registry general protocol and consent was approved by
the Duke University IRB (#Pro00054616) and at all participating site IRBs. Because the CTP study is not interventional and patients received standard-of-care therapy
at the discretion of their treating physician, additional
consent for participation beyond this standard consent
for the CARRA Registry was not required.
The entry criteria used were a CARRA-modified version of the International League of Associations of
Rheumatology (ILAR) criteria [20], as published in the
original article describing the development of the
systemic JIA CTPs [17]. In order to capture as many
children with systemic JIA as possible while avoiding
inclusion of children with self-limited febrile illnesses
or alternative diagnoses, it was decided by consensus of
the pediatric rheumatologists in the CARRA JIA Research Committee to adapt the ILAR criteria for newonset patients. The modifications were to require at
least 2 weeks of fever (but not necessarily on continuous days), at least one joint with physician-documented
arthritis for at least a week, along with at least one
other ILAR systemic JIA feature. No prior treatment
for systemic JIA aside from NSAIDs or short-term (less
than 2 weeks) GC were allowed. There was no
randomization or blinding of treatment assignment; instead, a CTP was chosen for each child by the treating
pediatric rheumatologist after discussion with the child
and family as part of customary clinical decision making process. The CTP choices were: (1) GC only; (2)
Methotrexate ± GC; (3) IL1i (either anakinra or canakinumab) ± GC [18]; and (4) IL6i (tocilizumab) ± GC.
Follow-up visits occurred at intervals defined by the
CTPs and consistent with routine care: 2 weeks, 1, 3, 6
and 9 months after baseline. Unscheduled visits were
conducted if there was a change in CTP medication.
Clinical and laboratory data, determined previously by
consensus-based process and also consistent with routine care, were collected at these time points through
the CARRA Registry as outlined in the CTPs [17]. The
CTPs recommended that if patients worsened or failed
to improve sufficiently as determined by the physician’s
assessment of disease activity, GC could be added or
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increased, or the treatment (CTP) changed. Suggested
GC tapering schedules corresponding to very rapid,
rapid, moderate, and slow tapering schedules were provided to be used by the treating physician but were not
compulsory. By 3 months after CTP initiation, if the
child was still receiving ≥50% of the starting dose of GC,
it was recommended that the treatment (CTP) should
be changed anticipating a better outcome. The treating
physicians were asked why a particular initial CTP was
chosen, and to provide the reason if the treating CTP
was changed. Serious adverse events, including macrophage activation syndrome (MAS), and side effects of
medications, were collected.
Outcomes included the primary endpoint of the
study: clinical inactive disease (CID) off glucocorticoids at 9 months. CID was defined using the ACR
provisional criteria for defining clinical inactive disease which specifies all the following: no active arthritis, a physician’s global assessment of disease activity
score of 0, ESR and/or CRP in the normal range, no
features of systemic JIA (fever, rash, serositis, splenomegaly, or generalized lymphadenopathy), no uveitis
and duration of morning stiffness for <15 min [21].
All inactive disease criteria [22] were available for all
children who had a documented 9 month visit. For
the primary endpoint analysis, all patients were included even if lost to follow-up. The GC and methotrexate CTP-initiated patients were combined as the
non-biologic CTP group, while the IL1i and IL6i CTP
initiated patients were combined as the biologic CTP
group. Secondarily, all 4 CTPs were analyzed separately assessing achievement of the primary endpoint,
as well as the ability to lower GC doses.
Safety assessments included reporting of serious adverse events (SAEs), defined as an adverse event that
results in death, is life-threatening, requires hospitalization
or prolongation of a hospitalization, persistent or significant disability or in capacity, or a congenital anomaly or
birth defect; and adverse events (AEs). AEs were graded
using Common Terminology Criteria for Adverse Events
(CTCAE v4.0). Grade 1 AE was asymptomatic or with
mild symptoms and required either clinical or diagnostic
observations or no intervention. Grade 2 AE was defined
as moderate severity requiring minimal, local or noninvasive intervention. Grade 3 was a severe or medically significant event but not immediately life-threatening and
either hospitalization or prolongation of hospitalization
were required. Grade 4 AEs were defined as those with
life-threatening consequences or requiring urgent intervention. The MedDRA dictionary was not used for safety
reporting in this pilot study.
Differences in data collected from the CTPs were
compared using chi square, Fisher’s exact, and Wilcoxon
rank sum tests.
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Results
Thirty untreated, mostly newly diagnosed systemic JIA
patients were enrolled into the CARRA Registry at 13
sites and started on a CARRA systemic JIA CTP. The
children’s clinical and demographic characteristics are
summarized in Table 1.
Five patients were taking GC prior to starting their respective CTP (median 12 days prior to baseline): of these
patients, three patients started on IL6i, and one each
started on IL1i and MTX. One patient started on the
IL1i CTP was lost to follow-up after the baseline visit.
Figure 1 shows the number of children in each CTP
group that eventually switched CTPs or added a
DMARD such as methotrexate. Ultimately, 12 of 30 children (40%) switched from their original CTP or added
methotrexate. Figure 2 shows initial CTP choice by site.
Sites 1–4 exclusively used non-biologic CTPs to start,
while sites 6–13 exclusively used biologic CTPs, with site
5 the only site to start both biologic and non-biologic
CTPs. Although the majority of sites enrolled few patients
(1 to 3), reasons for selecting a particular CTP varied
mostly by site rather than CTP. The most common reasons cited were: “treatment works best” in 19/29 (65.5%)
(GC, IL1i, IL6i CTPs); “treatment is safer” in 15/29
(51.7%) (MTX, IL1i, IL6i); “treatment is better tolerated”
in 14/29 (48.3%) (MTX, IL1i, IL6i); and “always select(s)
this treatment” in 10/29 (34.5%) (GC, IL1i, IL6i).
Owing to the reliance on data collection at regular office visits, there was variability in the designated 9 month
visit dates with the median being 39.9 weeks after baseline (IQR: 37.3, 43.4, range 29.9–54.7 weeks) Three children did not have a 9 month visit (1 GC and 2 IL1i CTP
patients); of these, 1 of the 2 IL1i treated patients and
the GC treated patient were lost to follow-up.
While feasibility of the study methodology rather than
clinical outcomes was the major purpose of this study,
and with the caveat that no attempt was made to adjust
for patient characteristics between these very small
groups, differences between non-biologic and biologic
CTPs were nevertheless observed. The primary endpoint
of CID off GC at 9 months was achieved by 50% of biologic CTP initiated children (11 of the 22 children),
whereas none of the eight non-biologic CTP initiated
children achieved this endpoint (p = 0.014) (Table 2).
This failure to achieve CID off GC was not simply due
to slow tapering of GC: 6 of 8 (75%) children started on
non-biologic CTPs had active disease at 9 months compared with 9 of 22 (41%) of children started on biologic
CTPs (p = 0.407); and 6 of 8 (75%) of non-biologic CTP
treated children were still taking GC at 9 months, compared to 4 of 22 (18%) of biologic CTP treated children
(p = 0.007). Table 3 also shows the primary endpoint
analysis by individual CTP group, as well as of patients
who achieved the endpoint without switching/adding
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Table 1 Baseline demographic and disease characteristics in all systemic JIA CTP patients
GC (N = 2)

MTX (N = 6)

IL1 Inhibitor (N = 12)

Age in years

12.8

3.4

4.0

9.8

5.7

0.047

Female

50%

67%

92%

90%

83%

0.3

0%

83%

33%

80%

57%

0.03

121

38

31

55

42.5

0.2

0%

50%

67%

80%

63%

0.18

Number of active joints

1.0

4.5

5.0

5.5

4.0

0.28

ESR >3x ULN

100%

67%

91%

43%

73%

0.27

CRP >3x ULN

100%

83%

91%

40%

79%

0.28

Ferritin (ng/mL)a

12,874

1,394

1,062

627

783

0.09

CHAQ scorea

0.9

1.3

1.9

0.8

1.4

0.6

Pain score (0–10)a

3

6.5

6

7.5

6

0.6

Physician global assessment
(0–10)a

4

7

5

5

5.5

0.12

Parent global assessment
well-being (0–10)a

0

7

6

6

6

0.103

Initiated GC at baseline

100%

100%

42%

70%

67%

0.029

Initial GC dose (mg/kg)a

0.67

0.97

0.00

0.68

0.80

0.548
0.350

a

White
Disease duration (days)

a

Polyarthritis
a

IL6 Inhibitor (N = 10)

Total (N = 30)

GC prior to baseline

50%

16.7%

8.3%

30%

20%

Initial dose of each CTP medication
in mg/kg (IQR)a

0.67 (0.6–0.73)

0.487 (0.46–0.64)

2.93 (2–3.6)b

8.14 (8–12)

Not Applicable

a

P-value

Median
Anakinra dose (anakinra was used as the initial IL-1i in all patients)

b

CTP medications. Likely due to the small numbers in
each group, statistical significance was not achieved
in these groups. All but one provider generally
followed the CTP GC tapering recommendations, so
that if by Month 3, if GC were not tapered to less
than 50% of the initial dose, treatment was intensified
or the CTP was changed. There was no significant
difference in the median number of days from baseline of the 9 month visit between the biologic

(282 days) and non-biologic (271 days) CTP groups
(p = 0.599), despite the variability in the 9 month visit
date discussed above.
Adverse events are listed in Table 3. There was one
Grade 4 AE infusion reaction with tocilizumab. There
were 4 SAE’s: 2 that resulted in hospitalization for
intravenous antimicrobial therapy (cellulitis in a child
taking canakinumab and GC [Grade 3] and varicella in a
child taking anakinra [Grade 3]), 1 hospitalization for

Fig. 1 Initial Consensus Treatment Plan (CTP) Choices and Subsequent Treatment Changes. The total numbers of patients started on each CTP
are shown, along with those remaining on the original CTP medication (dark blue), switching to a different CTP (green) or adding another CTP
medication (light blue). IL1i: IL1 inhibitor; IL6i: IL6 inhibitor
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Fig. 2 Initial Consensus Treatment Plan (CTP) Choice By Site. CTP choices distributed by site, showing that 4 sites started only a non-biologic CTP
(red colors), while 8 sites started only a biologic CTP (blue colors), IL1i: IL1 inhibitor; IL6i: IL6 inhibitor

The choice of plan varied by site/individual physician rather than disease characteristics of the individual child,
with the caveat that at most a few patients were treated
at each site. However, plan choice driven by site allows
for a “pseudo-block randomization” in the context of a
larger observational comparative effectiveness study. The
distribution of CTP usage followed results of surveys
conducted as part of the development of the original
CTPs [17], indicating that there continues to be substantial variability in physician practice with regard to initial
treatment choices for systemic JIA.
The results of this pilot study underline the need for a
larger definitive comparative effectiveness study assessing all 4 CTPs. The quandary about the safest and most
effective treatment of new-onset systemic JIA has been
informed by studies of the IL1i anakinra (recombinant
IL-1 receptor antagonist). Recent studies looking at early
use of anakinra in systemic JIA demonstrated a marked
reduction in the development of chronic persistent arthritis from a historical rate of 50–60% to less than 10%
[9, 11], a rate of response markedly distinct from that
observed in a randomized controlled trial of anakinra in

appendicitis and appendectomy on methotrexate and
GC, and 1 for macrophage activation syndrome (MAS)
in a child on tocilizumab (Grade 3). One additional child
who was receiving anakinra developed MAS and was
treated with oral prednisone without hospitalization
(Grade 2). All patients recovered uneventfully.

Discussion
This pilot study assessed the feasibility of using standardized CARRA CTPs for untreated systemic JIA, 90%
of whom had disease onset less than 4 months prior to
treatment, to evaluate the comparative effectiveness of
commonly used treatment approaches. Importantly, the
study established that the CARRA Registry and the coordinating center at the Duke Clinical Research Institute
(DCRI) could effectively operationalize and capture the
data for such a study, but it also demonstrated that better methods to decrease missing visits and data, and to
be able to capture clinical data between visits for the larger study were needed. Interestingly, each plan was used
with similar frequency aside from the GC-only plan,
confirming community equipoise on treatment selection.

Table 2 Achievement of Clinical Inactive Disease (CID) off Glucocorticoids (GC) in Non-Biologic and Biologic initiated patients
(primary endpoint), as well as in the 4 Consensus Treatment Plan (CTP) groups
Biologic grouping
a

a

Patient Status
at Month 9

Total N = 30

Gluco-corticoids
N=2

Methotrex-ate
N=6

IL1i N = 12

IL6i N = 10

p-value

Non-Biologic
CTP N = 8

Biologic
CTP N = 22

p-value

CID

13/30 (43.3%)

0/2

2/6 (33.3%)

5/12 (41.7%)

6/10 (60.0%)

0.549

2/8 (25.0%)

11/22 (50.0%)

0.407

Off GC

20/30 (66.7%)

1/2 (50.0%)

1/6 (16.7%)

10/12 (83.3%)

8/10 (80.0%)

0.019

2/8 (25.0%)

18/22 (81.8%)

0.007

CID off GC

11/30 (36.7%)

0/2

0/6

5/12 (41.7%)

6/10 (60.0%)

0.079

0/8

11/22 (50.0%)

0.014

CID off GC and
no CTP change

8/30 (26.7%)

0/2

0/6

3/12 (25.0%)

5/10 (50.0%)

0.168

0/8

8/22 (36.4%)

0.071

Also shown are all patients who achieved CID (regardless of GC), all patients who were off GC, and all patients who achieved CID off GC and did not change their
CTP treatments, at 9 months. Patients lost to follow-up were considered treatment failures
a
IL1i: IL-1 inhibitor; IL6i: IL-6 inhibitor

Kimura et al. Pediatric Rheumatology (2017) 15:23

Page 6 of 8

Table 3 Adverse events reported in all patients by CTP at time of event
CTP at time of AE

GC

MTX

IL-1 Inhibitor

IL-6 Inhibitor

Total

Grade 2

0

2 (allergic reaction [1],
arthritis flare [1])

5 (MAS [1], hepatitis [1], rash [1],
Strep pharyngitis [1], injection
site reaction [1])

8 (fever [1}, rash [1], arthritis flare [2],
headache [1], neutropenia [1], viral
illness [1], infusion reaction [1])

15

Grade 3

0

0

2 (infections)b

0

2

Grade 4

0

0

0

1 (infusion reaction)

1

1 (MAS)

3

SAE

0

a

1

b

2 (infections)

a

Appendicitis and appendectomy
b
1 varicella (anakinra), 1 cellullitis (canakinumab)

established chronic systemic JIA [2]. These studies raise
the possibility of a “window of opportunity” in early systemic JIA during which cytokine blockade could be especially effective [23]. Even though this pilot study
included small numbers of children who were followed
for only 9 months, the results indicate that untreated
systemic JIA patients started on IL-1i or IL-6i biologics
achieved the primary endpoint (CID off GC at 9 months)
more frequently than children not started on a biologic.
Children treated with non-biologic CTPs were more
likely to both have continued active disease and continue
to be treated with GC compared to those treated with
biologic CTPs. Whether this will hold true in a larger
population of children followed for a longer period of
time remains to be seen, as no attempt was made to correct for baseline clinical features or other potentially
confounding variables, rendering the conclusions of this
this pilot study far from definitive [19].
Study limitations include the observational design. As
noted, no adjustments were made to address confounding by indication (prescriber channeling). The basic CTP
approach assumes that treatment choice is determined
by physician preferences rather than patient disease
characteristics, and further assumes that individual physicians influence disease outcomes only through the
CTP choice. We observed evidence in favor of the first
assumption in this pilot study, but the latter assumption
is difficult to assess given the strong correlations between physician and treatment choice. Missing data
points and visits outside of the suggested visit schedule
were relatively common, limiting analysis of the results.
Children were sometimes started on medications, especially GC, prior to starting the CTP. Short-term use of
GC was allowed, which may have changed the baseline
disease characteristics of these patients. However, prior
treatment with GC is particularly difficult to avoid at
presentation of new onset systemic JIA, a phase of the
disease in which children are often acutely ill; excluding
these children could eliminate significant numbers of
children, particularly the sickest children. In addition,
patients were followed for a relatively short period of
time (9 months), with CID assessed at a single time
point that may incompletely reflect the treatment

response in this dynamic disease. Evaluation of stably inactive disease, such as clinical inactive disease for 6 consecutive months (i.e., clinical remission) and clinical
inactive disease for 12 consecutive months off of all
medications (i.e., clinical remission off medication) [21]
will be assessed in the larger CTP study informed by this
pilot, but was not able to be captured in this study. Data
collection through the CARRA Registry will allow assessment of long-term outcomes for decade or more
after Registry enrollment, including outcomes such as
medication safety and functional status as well as remission. Lastly, the small sample size, differences in the
demographics of the study cohort compared to other
systemic JIA cohorts, the short follow-up duration and
missing data limit the external validity of the results of
this pilot study.
The use of modified ILAR criteria for diagnosis may
affect the generalizability of the study results. It is recognized that many children with systemic JIA in the earliest
stages of disease require treatment, yet may not strictly
fulfill ILAR criteria (especially the requirement for 6 weeks
of arthritis) [24]. Indeed, the Yamaguchi criteria for Adult
Onset Still Disease (the adult correlate of systemic JIA)
does not require overt arthritis for diagnosis [25, 26]. It is
possible that use of these modified criteria by clinicians
other than experienced pediatric rheumatologists may
lead to misdiagnosis. We emphasize that it is critical to exclude other diagnoses that may be mistaken for systemic
JIA, such as infection, malignancy (in particular acute
lymphoblastic leukemia, lymphoma and neuroblastoma)
or genetic auto-inflammatory diseases prior to starting
treatment for systemic JIA using the CTPs, especially before treatment with GC. In cases where the diagnosis is
not based on the triad of characteristic fever, rash and
arthritis, the advice of an expert pediatric rheumatologist
should be sought.
The larger comparative effectiveness study, implementing the systemic JIA CTP study at 60 or more CARRA
Registry sites, will retain the observational study design including non-randomization of treatment allocation. This
study, termed the FiRst-line Options in Systemic JIA
Treatment (FROST), will address limitations recognized
in the pilot study including reducing important potential
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biases such as confounding by indication by using propensity
scoring, as well as instrumental variable and marginal structural model analyses. Bayesian analytic methods will also be
utilized for the larger study. Bayesian prior belief exercises
needed for the analyses were conducted at a recent CARRA
annual meeting. This pilot study was employed to inform
the power calculations for FROST, in which we plan to use
an intention-to-treat analytic approach (see Additional files
1 and 2). Aggressive efforts to improve data quality are
planned, including more rigorous site education and awareness, leveraging various forms of communication. More detailed information about GC use prior to and during
treatment will be obtained and analyzed. Children/parents
will be queried about symptoms and GC dose on a regular
basis using home electronic mobile device reporting. We will
collect detailed information about SAEs and important medical events (IME) throughout the CTP study (including
MedDRA coding of events). Lastly, important long-term follow up of children started on the CARRA systemic JIA
CTPs will be accomplished using existing CARRA Registry
infrastructure to follow all enrolled patients for 10 or more
years, including use of a call center to contact patients and
their families if the child transitions from pediatric to adult
care or moves to a non-participating center.
We observed a few unexpected patient characteristics
in this small pilot study, such as a female predominance,
whereas most large studies of systemic JIA have reported
a nearly equal female to male ratio [8, 9]. There were
also patients with longer than expected disease duration
prior to study enrollment. These differences are anticipated to be minimized by the inclusion of many more
patients into the larger FROST CTP study.

Conclusions
This pilot study of the four CARRA standardized CTPs
for untreated mostly new-onset systemic JIA successfully
demonstrated the feasibility of their implementation in a
larger observational comparative effectiveness study
using the CARRA Registry for data collection. FROST,
the planned follow-on larger, longitudinal study will establish whether biologic medications started early in the
disease course will result in better outcomes for children
with new onset systemic JIA.
Additional files
Additional file 1: Power Calculations for larger comparative
effectiveness research study of systemic JIA Consensus Treatment Plans
[27]. (DOC 24 kb)
Additional file 2: Table S1. Scenarios evaluated for degree of
imbalance in propensity score modeling. (DOC 28 kb)
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